Upadacitinib: One More Option in the Treatment of Patients with Rheumatoid Arthritis and Crohn's Disease

Del Giudice A, Giuggioli D, Bertani A and Sandri G

Rheumatology Unit, University of Modena and Reggio Emilia, Italy
Rheumatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy
Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Italy
Gastroenterology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy

^*Correspondance to: Adele Del Giudice 

 PDF  Full Text Case Report | Open Access

Abstract:

Arthritis and IBD are conditions that can occur in the same patient simultaneously. The complexity in managing these cases lies in detecting the signs and symptoms that point to the onset of the disease at an early stage, and in choosing an appropriate course of treatment to control the joint and intestinal aspects at the same time. In recent times, a new class of drugs has been added to the treatment options: JAK inhibitors (JAKi), of which Upadacitinib is one. Being able to manage and follow up with these patients in joint gastro-rheumatology outpatient clinics, where professionals from both disciplines are able to follow these cases appropriately, avoiding delays in diagnosis and treatment, is also important.

Keywords:

#

Cite the Article:

Del Giudice A, Giuggioli D, Bertani A, Sandri G. Upadacitinib: One More Option in the Treatment of Patients with Rheumatoid Arthritis and Crohn's Disease. Clin Case Rep Int. 2024; 8: 1677.